Page last updated: 2024-11-02

pindolol and Pancreatic Neoplasms

pindolol has been researched along with Pancreatic Neoplasms in 1 studies

Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.

Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ishizuka, J1
Beauchamp, RD1
Townsend, CM1
Greeley, GH1
Thompson, JC1

Other Studies

1 other study available for pindolol and Pancreatic Neoplasms

ArticleYear
Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells.
    Journal of cellular physiology, 1992, Volume: 150, Issue:1

    Topics: 8-Bromo Cyclic Adenosine Monophosphate; Cell Division; Cyclic AMP; Cyclic GMP; Ergolines; Humans; Pa

1992